ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

URGN UroGen Pharma Ltd

14.30
0.04 (0.28%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
UroGen Pharma Ltd URGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.04 0.28% 14.30 18:22:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
14.50 14.14 14.70 14.30 14.26
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/5/202414:20BWUroGen Announces Results from ATLAS Showing Robust UGN-102..
04/5/202410:50BWNew Real-World Study on Retrograde Instillation of JELMYTO®..
03/5/202407:00BWUroGen Pharma to Report 2024 First Quarter Financial Results..
17/4/202411:02BWUroGen Announces New Data Presentations at the American..
15/4/202407:00BWUroGen Announces FDA Acceptance of Investigational New Drug..
03/4/202407:00BWUroGen Pharma Files Patent Infringement Action Against Teva..
14/3/202407:00BWUroGen Pharma Delivers Double Digit JELMYTO® Growth and..
08/3/202407:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
04/3/202407:00BWUroGen Pharma to Report Fourth Quarter and Full-Year 2023..
04/3/202406:00EDGAR2Form 8-K - Current report
01/3/202406:00EDGAR2Form 8-K - Current report
26/2/202407:00BWUroGen Pharma to Present at TD Cowen 44th Annual Health Care..
12/2/202416:47EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
07/2/202415:15EDGAR2Form 8-K - Current report
02/2/202418:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202409:13EDGAR2Form 144 - Report of proposed sale of securities
01/2/202408:53EDGAR2Form 144 - Report of proposed sale of securities
01/2/202407:00BWUroGen Pharma to Participate at Upcoming Investor..
24/1/202407:00BWUroGen Initiates Submission of a Rolling NDA to the FDA for..
17/1/202415:16EDGAR2Form 8-K - Current report
17/1/202407:00BWUroGen Secures Exclusive License from medac GmbH to Develop..
11/1/202407:00BWUroGen Pharma to Participate in the B. Riley Healthcare..
02/1/202407:04EDGAR2Form 8-K - Current report
08/12/202315:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
14/11/202315:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/11/202307:00BWUroGen Pharma Reports Third Quarter 2023 Financial Results
13/11/202307:00BWUroGen will Present Scientific Advances in Bladder Cancer at..
07/11/202307:00BWUroGen Pharma to Report Third Quarter 2023 Financial Results..
03/10/202307:00BWFollowing Pre-NDA Meeting with the FDA, UroGen Announces..
11/9/202315:15EDGAR2Form 8-K - Current report
11/9/202306:00GLOBEEledon Pharmaceuticals Appoints Industry Veteran James..
08/9/202315:16EDGAR2Form S-3 - Registration statement under Securities Act of..
08/9/202314:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202314:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202307:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
05/9/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/8/202307:00BWUroGen Pharma to Present at Upcoming Investor Conferences
10/8/202307:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202307:01EDGAR2Form 8-K - Current report
10/8/202307:00BWUroGen Pharma Reports Record JELMYTO Quarterly Sales and..
08/8/202307:00BWThe Journal of Urology Publishes Peer-Reviewed Article..
04/8/202307:56EDGAR2Form SC 13D - General statement of acquisition of beneficial..

Su Consulta Reciente

Delayed Upgrade Clock